Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 6/20 | 0.43 |
| ▸ | CKS1B | P61024 | 6/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 6/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.36 |
| ▸ | CCR8 | P51685 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1103061 | 0.89 | CKS1B (0.48) | TOP1CKS1BSKP2GLO1COMT | |
| SCHEMBL1103120 | 0.85 | L3MBTL1 (0.42) | TOP1CKS1BSKP2GLO1L3MBTL1 | |
| SCHEMBL1103109 | 0.85 | L3MBTL1 (0.42) | TOP1CKS1BSKP2GLO1L3MBTL1 | |
| SCHEMBL1103081 | 0.85 | L3MBTL1 (0.42) | TOP1CKS1BSKP2GLO1L3MBTL1 | |
| SCHEMBL1103115 | 0.85 | L3MBTL1 (0.42) | TOP1CKS1BSKP2GLO1L3MBTL1 | |
| SCHEMBL1102913 | 0.84 | TOP1 (0.38) | TOP1L3MBTL1PIK3CDALDH1A1 | |
| SCHEMBL1103113 | 0.83 | ESR1 (0.41) | TOP1CKS1BSKP2GLO1CCR1 | |
| SCHEMBL1103108 | 0.83 | ESR1 (0.41) | TOP1CKS1BSKP2GLO1CCR1 | |
| SCHEMBL1103097 | 0.83 | L3MBTL1 (0.41) | TOP1CKS1BSKP2GLO1L3MBTL1 | |
| SCHEMBL1102949 | 0.83 | L3MBTL1 (0.41) | TOP1CKS1BSKP2GLO1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| EP-2147962-A1 | Azaanthracene-derivatives and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | TOP1 4307/4885CKS1B 3839/4885SKP2 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.